Ginkgo Bioworks Holdings Inc (DNA) Reports Q1 2024 Results: A Comprehensive Overview
Ginkgo Bioworks Holdings Inc (DNA) Reports Decline in 2023 Revenue Amid Transition and ...
Ginkgo Bioworks Holdings Inc (DNA) Reports Q3 2023 Financial Results
Director Christian Henry Sells 4,499 Shares of Ginkgo Bioworks Holdings Inc (DNA)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ginkgo Bioworks Holdings Inc. (DNA) Investigation
NEW YORK--(BUSINESS WIRE)--$DNA #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soaring Eagle Acquisition Corp., whi
Ginkgo Bioworks Holdings Inc. Price Target Cut to $6.00/Share From $10.50 by Raymond James
Ginkgo Bioworks Holdings Inc. Price Target Cut to $6.00/Share From $10.50 by Raymond James
Ginkgo Bioworks Holdings Inc Price Target Raised to $14.50/Share From $11.50 by Raymond James
Ginkgo Bioworks Holdings Inc Price Target Raised to $14.50/Share From $11.50 by Raymond James
Ginkgo Bioworks Holdings Inc. Price Target Is Maintained at $11.50/Share by Raymond James
Ginkgo Bioworks Holdings Inc. Price Target Is Maintained at $11.50/Share by Raymond James
Penny Stocks To Buy In May? 3 To Watch Before Next Week
If you're looking for penny stocks to buy, this market offers incredible opportunities. With how stock market volatility has been this month, a fast hand and a keen eye are crucial. When they say that
Ginkgo Bioworks Holdings Inc Price Target Is Maintained at $11.50/Share by Raymond James
Ginkgo Bioworks Holdings Inc Price Target Is Maintained at $11.50/Share by Raymond James
Ginkgo Bioworks Holdings Inc Is Maintained at Outperform by Raymond James
Ginkgo Bioworks Holdings Inc Is Maintained at Outperform by Raymond James
Is Ginkgo Bioworks a Buy Under $5?
Analysts updated their earnings model after the company reported its yearly results, predicting its losses to decline to $0.16 per share this year. However, analysts had earlier predicted losses would decline to $0.12 per share, indicating an increase in loss per share expectations.DNA’s stock has declined 63.8% in price since it went public on Sept. 17, 2021, and 50.3% year-to-date. But the stock gained 20.4% over the past month to close yesterday’s trading session at $4.13.
Ginkgo Bioworks Holdings Inc. Price Target Cut to $11.50/Share From $14.50 by Raymond James
Ginkgo Bioworks Holdings Inc. Price Target Cut to $11.50/Share From $14.50 by Raymond James
Did The Smart Money Play Ginkgo Bioworks Holdings Inc. (DNA) Correctly?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
DNA; SRNG Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors With Losses Exceeding $200K of Class Action
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings Inc. ("Ginkgo" or
Ginkgo Bioworks Holdings Inc. Price Target Is Maintained at $14.50/Share by Raymond James
Ginkgo Bioworks Holdings Inc. Price Target Is Maintained at $14.50/Share by Raymond James
Ginkgo Bioworks Holdings Inc. Is Maintained at Outperform by Raymond James
Ginkgo Bioworks Holdings Inc. Is Maintained at Outperform by Raymond James
DNA; SRNG Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors of Class Action and Lead Plaintiff Deadline: January 18, 2022
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings
GINKGO BIOWORKS HOLDINGS, INC. F/K/A SOARING EAGLE ACQUISITION CORP. (NYSE: DNA, SRNG) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Ginkgo Bioworks Holdings, Inc.
NEW YORK, Nov. 19, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors wh
Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
Selecta Biosciences Inc (NASDAQ:SELB) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. The partner
No Data